Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.55 |
| ▸ | CNR2 | P34972 | 5/20 | 0.55 |
| ▸ | CNR1 | P21554 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | RORA | P35398 | 1/20 | 0.45 |
| ▸ | RORB | Q92753 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27812675 | 0.84 | NR1I2 (0.64) | NR1I2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL21115115 | 0.77 | RORC (0.46) | NR1I2KMT2AMAPTALDH1A1POLB | |
| SCHEMBL28134914 | 0.77 | PKM (0.55) | NR1I2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL16540121 | 0.77 | CNR2 (0.51) | NR1I2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL16731518 | 0.74 | RORC (0.81) | NR1I2MAPTALDH1A1RORCRORA | |
| SCHEMBL12218485 | 0.74 | KMT2A (0.69) | CNR2CNR1KMT2AMEN1MAPT | |
| SCHEMBL10438567 | 0.72 | ESR1 (0.79) | NR1I2KMT2AMEN1ESR1TSHR | |
| SCHEMBL3156533 | 0.71 | NR3C1 (0.51) | NR1I2RORCESR1RORARORB | |
| SCHEMBL28129570 | 0.71 | MCL1 (0.62) | NR1I2KMT2AMAPTPOLBRORC | |
| SCHEMBL15980998 | 0.70 | MCL1 (0.63) | KMT2AMEN1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
| WO-2018055316-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | NR1I2 1005/4885CNR2 840/4885CNR1 930/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | NR1I2 1229/4885CNR2 1043/4885CNR1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.